Proprietary Portfolio (via IcanoMAB spin-off)
Oncology (Immuno-oncology, Solid Tumors), Acute Inflammation (e.g., COVID-19 ARDS/CRS), Immune-modulation (e.g., MAS, SJIA, IBD, Gout)
Key Facts
About MAB Discovery
MAB Discovery is a Munich-based antibody discovery company with a proven track record of generating therapeutic mAbs for pharmaceutical partners, with eight partner projects reaching the clinic by 2023. Following the 2019 sale of its laboratory platform to BioNTech, the company restructured, spinning out its proprietary clinical-stage assets into a separate entity, IcanoMAB, which it continues to advance through a network of collaborations. MAB Discovery now operates as an asset-centric entity, leveraging its discovery expertise and network to progress its retained portfolio while maintaining its partner-focused service legacy.
View full company profile